Key result
In stage D heart failure, hemodialysis patients had significantly elevated steady-state milrinone concentrations compared to those with normal renal function (6252 vs 451 ng/mL; P<0.05).
Why the study?
Does renal dysfunction increase steady state plasma milrinone concentrations in patients with stage D heart failure?
Cohort (n=29)
No
Does renal dysfunction increase steady state plasma milrinone concentrations in patients with stage D heart failure?
p-value: p=<0.05
In patients with stage D heart failure, severe renal dysfunction is associated with markedly elevated steady-state milrinone concentrations and a potential increased risk of ventricular arrhythmias.
No takes yet. Share an insight, caveat, or question.
May warrant therapeutic drug monitoring in hemodialysis patients; leaves open whether concentration-guided dosing reduces arrhythmias in stage D heart failure.
Cox et al. (2013) conducted a cohort in Stage D heart failure (n=29). Continuous milrinone infusion vs. Stratification by creatinine clearance (CrCl >60, 60-30, <30 mL/min, and intermittent hemodialysis) was evaluated on Steady state milrinone concentrations (p=<0.05). In stage D heart failure, hemodialysis patients had significantly elevated steady-state milrinone concentrations compared to those with normal renal function (6252 vs 451 ng/mL; P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: